Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic biomarkers: cytochrome P450 3A5.

Clinica chimica acta; international journal of clinical chemistry - 8 Sept 2012

MacPhee Iain A M

Abstract excerpt

The immunosuppressive drugs used for solid organ transplantation all have a narrow therapeutic index with wide variation between individuals in the blood concentration achieved by a given dose. Therapeutic drug monitoring is employed routinely but may not allow optimisation of drug exposure during the critical period two to three days following transplantation. A key factor in the inter-individual variability for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP3A
Share to Alleles
Share to Biomarkers, Pharmacological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A Inhibitors

Share to Immunosuppressive Agents

Share to Organ Transplantation

Share to Tacrolimus

Share to Uremia

Source

Identifiers

PMID: 22037511
DOI: 10.1016/j.cca.2011.10.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic biomarkers: cytochrome P450 3A5.PMID 22037511Read ↗

Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation.Semantic proximity Read ↗

Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.Semantic proximity Read ↗

Use of pharmacogenetics to optimize immunosuppressive therapy.Semantic proximity Read ↗

A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype.Semantic proximity Read ↗

Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?Semantic proximity Read ↗

Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.Semantic proximity Read ↗

Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs.Semantic proximity Read ↗

[Pharmacogenetics of tacrolimus: from bench to bedside?].Semantic proximity Read ↗

Current progress of tacrolimus dosing in solid organ transplant recipients: Pharmacogenetic considerations.Semantic proximity Read ↗

Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome.Semantic proximity Read ↗

CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.